La noradrenalina como tratamiento médico alternativo a la terlipresina en el manejo del síndrome hepatorrenal tipo 1

Sendra, Carmen; Silva Ruiz, María del Pilar; Ferrer Rios, María Teresa; Alarcón García, José Carlos; Pascasio Acevedo, Juan Manuel.
Gastroenterol. hepatol. (Ed. impr.) ; 41(7): 440-441, ago.-sept. 2018. graf
Artículo en Español | IBECS (España) | ID: ibc-180624

Documentos relacionados

  1. Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial.
  2. Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives.
  3. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
  4. The Treatment of Hepatorenal Syndrome.
  5. Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
  6. [A comparative study of high-or low-dose terlipressin therapy in patients with cirrhosis and type 1 hepatorenal syndrome].
  7. Terlipressin Treatment Is Associated With Reversal of Hepatorenal Syndrome in Patients With Alcoholic Hepatitis.
  8. Reply: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?
  9. A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock.
  10. Type-1 hepatorenal syndrome in patients with cirrhosis and infection vs. sepsis-induced acute kidney injury: what matters?